Cantor Fitzgerald Reiterates Overweight on Editas Medicine, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Rick Bienkowski has reiterated an Overweight rating on Editas Medicine (NASDAQ:EDIT) and maintained a $15 price target.
June 13, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst maintains Overweight rating and $15 price target on Editas Medicine (NASDAQ:EDIT).
The reiteration of the Overweight rating and maintenance of the $15 price target by Cantor Fitzgerald's analyst indicates a positive outlook for Editas Medicine. This could lead to a short-term increase in the stock price as investors may perceive the rating as a sign of confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100